{
    "clinical_study": {
        "@rank": "4960", 
        "arm_group": {
            "arm_group_label": "Perampanel", 
            "description": "Perampanel tablets are administered orally according to prescribing information and the treating physician's clinical judgment"
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to evaluate the safety and tolerability of Fycompa (Perampanel)\n      as an add-on therapy in epilepsy patients aged greater than or equal to 12 years."
        }, 
        "brief_title": "A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years", 
        "completion_date": {
            "#text": "June 2017", 
            "@type": "Anticipated"
        }, 
        "condition": "Epilepsy", 
        "condition_browse": {
            "mesh_term": "Epilepsy"
        }, 
        "detailed_description": {
            "textblock": "This is a global, observational, cohort study in patients with epilepsy. Multiple treating\n      physicians will prescribe perampanel to approximately 500 patients, who then will be\n      observed for approximately 52 weeks."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n          1. Male or female patients age greater than or equal to 12 years (or as regionally\n             appropriate) at the time of informed consent\n\n          2. Patients prescribed perampanel for the adjunctive treatment of epilepsy within 7 days\n             of the Screening Visit\n\n          3. Patients who provide informed consent\n\n        Exclusion Criteria\n\n          1. Participation in another study involving administration of an investigational drug or\n             device whilst participating in this observational study\n\n          2. Prior participation in a perampanel clinical study\n\n          3. Hypersensitivity to perampanel"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "12 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Epilepsy patients prescribed adjunctive treatment in countries where perampanel has\n        received marketing approval.  Multiple treating physicians will prescribe perampanel to\n        patients, who then will be observed for approximately 52 weeks."
            }
        }, 
        "enrollment": {
            "#text": "500", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "December 17, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02033902", 
            "org_study_id": "E2007-G000-402"
        }, 
        "intervention": {
            "arm_group_label": "Perampanel", 
            "description": "Perampanel tablets are administered orally according to prescribing information and the treating physician's clinical judgment", 
            "intervention_name": "Perampanel", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Epilepsy", 
        "lastchanged_date": "March 28, 2014", 
        "number_of_groups": "1", 
        "official_title": "A Global, Postmarketing Observational Safety Study to Evaluate the Safety and Tolerability of Fycompa (Perampanel) as Add-on Therapy in Epilepsy Patients Aged Greater Than or Equal to 12 Years", 
        "overall_contact": {
            "last_name": "Eisai Medical Services", 
            "phone": "1-888-422-4743"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Austria: Agency for Health and Food Safety", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "May 2017", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Assessment of events of dizziness, blurred vision, somnolence, aggression, balance disorders, ataxia, falls, unintended pregnancy, weight gain, suicidality, drug abuse, misuse, dependence, withdrawal, off-label use, skin photosensitivity, unintended pregnancy while taking levonorgestrel-containing contraceptives, and outcomes associated with any suspected drug-drug interaction.", 
            "measure": "Number of Treatment Emergent Adverse Events (TEAEs) of interest", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 52 weeks and 2 weeks of follow-up"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02033902"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Incidence of unintended pregnancy", 
                "safety_issue": "No", 
                "time_frame": "Up to 52 weeks"
            }, 
            {
                "measure": "Incidence of off-label use", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 52 weeks"
            }, 
            {
                "measure": "Summary scores for the Hospital Anxiety and Depression Scale (HADS)", 
                "safety_issue": "Yes", 
                "time_frame": "Screening, Week 52"
            }, 
            {
                "description": "TEAEs observed in the specified subpopulations of patients could also be made in order to get a better understanding of whether any of these particular potential risk factors (e.g., old age, cardiovascular disease) define groups with greater or lesser risk.", 
                "measure": "Number of TEAEs in the patient subpopulations of interest", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 52 weeks and 2 weeks of follow-up"
            }, 
            {
                "description": "Assessment of disease severity will utilize the Clinical Global Impression of Change (CGI-C) scale at end of treatment to evaluate change in disease status since initiation of treatment.", 
                "measure": "Clinical Global Impression of Change", 
                "safety_issue": "No", 
                "time_frame": "Week 52"
            }
        ], 
        "source": "Eisai Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eisai Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "March 2014"
    }
}